<DOC>
	<DOC>NCT00599755</DOC>
	<brief_summary>This study will use imaging to look at tumor response to combination chemotherapy of gemcitabine (Gem) and cisplatin (Cis) or gemcitabine and carboplatin (Carbo) in non small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Has histologically or cytopathologically confirmed metastatic or locally advanced stage IIIB/IV Nonsmall cell lung cancer (NSCLC) Has measurable disease Has not been previously treated with surgery (involving the thorax), radiation (unless it was for a metastatic site), or chemotherapy for NSCLC Is 18 years of age or older Has a performance status of 02 on the Eastern Cooperative Oncology Group (ECOG) scale Women of childbearing potential have a negative pregnancy test Is participating in or has participated in a study with an investigational compound or device within 30 days or 5 halflives of the start of treatment Has untreated brain metastases related to their NSCLC or carcinomatous meningitis Abuses drugs or alcohol Is pregnant or breastfeeding Is Human Immunodeficiency Virus (HIV) positive Has active viral hepatitis Has hearing loss Has poorly controlled diabetes mellitus Is allergic to gemcitabine, cisplatin or carboplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>